Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pancreatic cancer risk after treatment of Hodgkin lymphoma.
Dores GM, Curtis RE, van Leeuwen FE, Stovall M, Hall P, Lynch CF, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Joensuu H, Johannesen TB, Andersson M, Holowaty EJ, Kaijser M, Pukkala E, Vaalavirta L, Fossa SD, Langmark F, Travis LB, Fraumeni JF Jr, Aleman BM, Morton LM, Gilbert ES. Dores GM, et al. Among authors: van leeuwen fe. Ann Oncol. 2014 Oct;25(10):2073-2079. doi: 10.1093/annonc/mdu287. Epub 2014 Jul 25. Ann Oncol. 2014. PMID: 25185241 Free PMC article.
Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.
van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JM, Somers R. van Leeuwen FE, et al. Among authors: van den belt dusebout aw. J Natl Cancer Inst. 1995 Oct 18;87(20):1530-7. doi: 10.1093/jnci/87.20.1530. J Natl Cancer Inst. 1995. PMID: 7563187
Risk of endometrial cancer after tamoxifen treatment of breast cancer.
van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrère CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, et al. van Leeuwen FE, et al. Lancet. 1994 Feb 19;343(8895):448-52. doi: 10.1016/s0140-6736(94)92692-1. Lancet. 1994. PMID: 7905955 Free article.
Risk of leukemia following treatment for non-Hodgkin's lymphoma.
Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM, et al. Travis LB, et al. Among authors: van leeuwen fe. J Natl Cancer Inst. 1994 Oct 5;86(19):1450-7. doi: 10.1093/jnci/86.19.1450. J Natl Cancer Inst. 1994. PMID: 8089863
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, van Heerde P, Somers R. van Leeuwen FE, et al. Among authors: van heerde p, van den belt dusebout aw, van kerkhoff eh. J Clin Oncol. 1994 Feb;12(2):312-25. doi: 10.1200/JCO.1994.12.2.312. J Clin Oncol. 1994. PMID: 8113838
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EH, Pinedo HM, Somers R. van Leeuwen FE, et al. Among authors: van den belt dusebout aw, van kerkhoff eh. J Clin Oncol. 1994 May;12(5):1063-73. doi: 10.1200/JCO.1994.12.5.1063. J Clin Oncol. 1994. PMID: 8164031
492 results